- Open Access
Endomyocardial biopsies in patients with left ventricular hypertrophy and a common Chinese later-onset fabry mutation (IVS4 + 919G > A)
- Ting-Rong Hsu1, 2,
- Shih-Hsien Sung3,
- Fu-Pang Chang4,
- Chia-Feng Yang2,
- Hao-Chuan Liu2,
- Hsiang-Yu Lin5,
- Chun-Kai Huang2, 6,
- He-Jin Gao2, 6,
- Yu-Hsiu Huang2, 6,
- Hsuan-Chieh Liao7,
- Pi-Chang Lee2,
- An-Hang Yang4,
- Chuan-Chi Chiang7,
- Ching-Yuang Lin8,
- Wen-Chung Yu3Email author and
- Dau-Ming Niu1, 2, 6Email author
© Hsu et al.; licensee BioMed Central Ltd. 2014
- Received: 24 February 2014
- Accepted: 19 June 2014
- Published: 1 July 2014
In Taiwan, DNA-based newborn screening showed a surprisingly high incidence of a cardiac Fabry mutation (IVS4 + 919G > A). The prevalence of this mutation is too high to be believed that it is a real pathogenic mutation. The purpose of this study is to identify the cardiac pathologic characteristics in patients with left ventricular hypertrophy and this mutation
Methods and results
Endomyocardial biopsies were obtained in 22 patients (Median age: 61, males: 17; females: 5) with left ventricular hypertrophy and the IVS4 + 919G > A mutation; five patients had not received enzyme replacement therapy (ERT) before biopsy, while the other 17 patients had received ERT from 8 months to 51 months. Except for three patients who had received ERT for more than 3 years, all other patients showed significant pathological change and globotriaosylceramide (Gb3) accumulation in their cardiomyocytes. In contrast to classical Fabry patients, no Gb3 accumulation was found in the capillary endothelial cells of any of our patients. Fourteen patients (63.6%) were found to have myofibrillolysis.
All of the untreated and most of the treated IVS4 + 919G > A patients showed typical pathological changes of Fabry disease in their cardiomyocytes. No endothelial accumulation of Gb3 was found, which is similar to the findings of several previous reports regarding later-onset Fabry disease. This result highly suggests that the IVS4 + 919G > A is a real pathogenic later-onset Fabry mutation.
- Endomyocardial biopsy
- Enzyme replacement therapy
- Fabry disease
- IVS4 + 919G > A
- Left ventricular hypertrophy
Fabry disease (MIM 301500) is an X-linked lysosomal storage disorder resulting from deficient alpha-galactosidase A (α-Gal A) activity. The estimated incidence of classic Fabry disease is 1 in 40,000-60,000 males in the general population . The deficient α-Gal A activity results in progressive accumulation of glycosphingolipid, predominantly globotriaosylceramide (Gb3), in the walls of small blood vessels, nerves, dorsal root ganglia, renal glomerular and tubular epithelial cells, and cardiomyocytes. Clinical features in classically affected patients include acroparesthesia, angiokeratoma, and hypohidrosis in early childhood or adolescence and progress to renal insufficiency, cardiomyopathy, and cerebrovascular disease in adulthood [2–6]. Recently, several different later-onset phenotypes of Fabry disease have been identified, which have drawn the attention of more physicians [7–9]. Patients with later-onset Fabry disease have higher residual enzyme activities than those of the classical type. They lack the classic symptoms of Fabry disease and present relatively fewer or isolated symptoms such as hypertrophic cardiomyopathy, renal failure, or cryptogenic stroke at later stages in life [10–14]. The cardiac later-onset phenotype usually presents only with cardiac manifestations, such as hypertrophic cardiomyopathy, mitral insufficiency and/or arrhythmias in the fifth to eighth decade [12, 15, 16].
Due to the high prevalence of IVS4 + 919G > A mutation in our population, a new treatment guideline has been set up by the Bureau of National Health Insurance in Taiwan. All Fabry patients applying for enzyme replacement therapy (ERT) funding from the national health insurance have to receive an endomyocardial biopsy examination to demonstrate that Fabry disease is the primary cause of their hypertrophic cardiomyopathy. This guideline gives us the opportunity to observe a large series of cardiac pathologic changes in these patients with left ventricular hypertrophy and the IVS4 + 919G > A mutation.
A total of 22 Fabry patients (17 males and 5 females, median age: 61 years old) with left ventricular hypertrophy carrying the IVS4 + 919G > A mutation were enrolled in this study. The demographic data, laboratory results, image results and pathologic findings of the endomyocardial biopsies were collected retrospectively from December 2012 to April 2013.
Five patients (nos.1-5) did not receive ERT before endomyocardial biopsy. The others had received agalsidase alfa (Replagal®, Shire) 0.2 mg/kg every other week as the enzyme replacement therapy for at least 8 months (range 8-40 months). Two patients (nos. 16 and 17) had initially received agalsidase beta (Fabrazyme®, Genzyme) 1 mg/kg every other week and then changed to Replagal® 0.2 mg/kg in 2009 owing to the global shortage of Fabrazyme.
The study complies with the Declaration of Helsinki and is approved by the medical ethics committee of Taipei Veteran General Hospital. Written informed consents were obtained.
GLA gene mutation
Blood samples were obtained from these patients in blood collecting tubes containing ethylene diamine tetraacetic acid, and samples were stored at 4°C. DNA was isolated from whole blood using the GFX genomic Blood DNA Purification Kit (Amersham Biosciences, UK) following the manufacturer’s instructions. The primer sets were used to amplify the sequences of seven GLA exons and the region including IVS4 + 919G > A [24, 25]. The polymerase chain reaction products were analyzed by 1.5% agarose I (Amresco) gel electrophoresis and then eluted in the polymerase chain reaction Advanced PCR Clean Up System (Viogene, USA.). Direct sequencing of the α-Gal A gene was processed using the BigDye Terminator v3.1 Cycle Sequencing Kit (Applied Biosystems) and ABI Prism 3730 Sequencer .
Plasma α-Gal A activity and Plasma LysoGb3
Plasma α-Gal A activity was determined using the substrate 4-methylumbelliferyl α-D-galactopyranoside (5 mmol/L) freshly prepared in 117 mmol/L N-acetyl-D-galactosamine/50 mmol/L citric-phosphate buffer, pH 4.6, before every assay. In brief, 50 μL of plasma was mixed with 300 μL of the substrate solution, incubated at 37°C for 2 hours, and 0.2 N glycine-NaOH was added to stop the reaction. Fluorescence intensity was measured with the excitation and emission wavelengths of 365 and 450 μm, respectively [27, 28]. Plasma LysoGb3 was detected by tandem mass spectrometry that was performed in positive ion mode (ES+) on a triple quadruple mass spectrometer (Quattro Ultima, Waters, Milford, MA) with NeoLynx software version 4.1. A multiple reaction monitoring (MRM) mode was used for the measurement of lysoGb3. The analyzing methods were modified from the protocol provided by Shire .
Echocardiography was performed routinely for the Fabry patients to check the hypertrophic cardiomyopathy. Left ventricular mass was calculated according to the Devereux cube formula and indexed to height2.7 (LVMI). Left ventricular hypertrophy by echocardiography was defined by a LVMI of >47 g/m2.7 in women or >50 g/m2.7 in men [30–32]. To avoid variability of LMVI measurements, only the results performed by two cardiologists specializing in echocardiography and measured with the same machine and protocol were used in this study.
Cardiac magnetic resonance imaging
Magnetic resonance imaging (MRI) of the heart was carried out as part of stand assessment on a 1.5 T scanner (Excite II; GE medical systems, Milwaukee, WI). Late enhancement (LE) technique by gadolinium-contrast cardiac MRI examination was applied for the later-onset Fabry patients for assessment of fibrosis. The participants underwent a scan with spin echo double IR T1WI and T2WI pulse sequences and Fiesta pulse sequence, on axial, coronal, and variable scanning plans. Images were acquired 10 minutes after the intravenous injection of gadolinium. The myocardial delayed enhancement protocol included the pre-Gd axial FIESTA cine and grid tagging in 8 mm slice, and the post-Gd myocardial delayed enhancement of short axis/four-chamber views in 8-mm slice and oblique axial cine of ascending aorta in 8-mm slice to detect changes in tissue integrity in the left ventricle myocardium [33–35]. Severe myocardial fibrosis was defined by at least two affected left ventricular segments, which are followed by the American heart association guideline , and mild myocardial fibrosis was defined by one segment affected.
Cardiac catheterization and endomyocardial biopsy
Right heart catheterization was approached via the right internal jugular vein under digital X-ray guidance. A flexible endomyocardial bioptome was inserted into the right ventricle and 2-3 specimens were obtained from interventricular septum and submitted to histological examination.
Cardiac specimens selected for light microscope were fixed in 10% buffered formalin, embedded in paraffin. The sections were cut from the paraffin block and stained with haematoxylin and eosin (H&E), and Masson’s trichrome. Cardiac specimens selected for electron microscope were fixed in 2.5% glutaraldehyde in phosphate buffer, post-fixed with 1% OsO4 in Sorenson’s phosphate buffer, followed by dehydration through a graded series of ethanol washes, and embedded in Spurr’s EPON. Semithin sections were cut from the block and stained with toluidine blue for adequate preview under a microscope. Ultrathin sections were prepared and examined under an electron microscope.
In the idealized model of a cardiomyocyte, as an elliptic cylinder, different diameters such as major axis (longest diameter) or minor axis (shortest diameter), etc. are measured, even in one transverse section of a cardiomyocyte. The current study revealed that, in the transverse section, the ratio between the major axis and minor axis of the cardiomyocytes is usually around 1.1 (11/10) . Therefore, the diameters of cardiomyocytes in transverse section can be approximately estimated. Because the minor axis of the transverse section of cardiomyocytes can be measured more easily and reliably than other diameters of the other axis, the diameter of the minor axis of the transverse section of cardiomyocytes was used to present the diameter of cardiomyocytes in several previous reports [38–41]. In accordance with these previous reports, we measured the minor axis at the nuclear level in transverse section to present the diameter of cardiomyocytes of our patients in this study. A total of 15 cells from 3 micrographs were measured for each sample. Control samples were retrospectively obtained from 8 anonymous patients who were provided by the department of pathology in our medical center. All the samples were obtained during the electrophysiology study for arrhythmia. None of these patients had any evidence of hypertrophic cardiomyopathy. All the histopathologic specimens were blindly reviewed by the same pathologist.
Data analysis and statistics
The data in some parts of the study were analyzed with descriptive statistics (mean, standard deviation). Due to the small number of patients and the uncontrolled nature of this study, no inferential statistics were used. Results are presented as actual measurements from individual patients. SPSS Version 20 (SPSS Inc, Chicago, Illinois, USA) was used for descriptive statistics.
The demographic data and clinical manifestations of the Fabry disease patients with IVS4 + 919G > A mutation
34.7 ± 4.4
Hyperlipidemia; Hepatitis B
21.8 ± 3.3
Coronary artery disease; Arrhythmia; Hepatitis C; Cholecystitis
31.5 ± 4.0
DM; Hypertension;ESRD s/p renal transplantation; Cholecystitis; Hyperuricemia
30.8 ± 5.6
Hypertension; Coronary artery disease; Hyperlipidemia; Hyperuricemia
33.5 ± 8.0
24.1 ± 2.4
Cubital tunnel syndrome
25.9 ± 2.8
Hypertension; DM; Duodenal ulcer
25.6 ± 7.0
Hyperlipidemia; Sick sinus syndrome
24.9 ± 3.6
Coronary artery disease; Fatty liver
21.1 ± 5.0
BPH; Bladder cancer; Osteoarthritis
21.6 ± 4.0
Hyperlipidemia; Arrhythmia s/p pacemaker
23.2 ± 3.4
26.2 ± 5.6
24.0 ± 5.4
24.2 ± 4.1
23.1 ± 4.1
Hypertension; DM; BPH
23.6 ± 3.8
Lung adenocarcinoma; Hypertension; Insomnia
24.6 ± 3.4
20.5 ± 3.3
Hypertension; Major depression
25.8 ± 6.9
23.5 ± 3.5
Chronic renal insufficiency; Hyperuricemia
23.5 ± 7.1
Recently, the later-onset phenotypes of Fabry disease were found to be about 10 times more frequent in most populations [1, 20, 42, 43]. Owing to the characteristics, the terminology “later-onset” Fabry disease might be more appropriate than “variant” Fabry disease. In fact, an increasing number of novel mutations have been found and believed to be later-onset mutations through high-risk patient screenings or newborn screenings. On the other hand, some mutations, which were previously thought to be later-onset mutations, have been proved to be non-pathogenic. The most noticeable example is the p,E66Q mutation (c.196G > C), a previously identified renal later onset type mutation, which has a very high prevalence rate in Japanese and Korean populations (0.5-1%) and which has now been proved by pathologic studies to be merely a single nucleotide polymorphism, not a pathogenic mutation . Therefore, it is insufficient to confirm a later onset mutation based on its enzyme activity and clinical manifestations such as hypertrophic cardiomyopathy or renal impairment.
Biomarkers, such as Gb3 or lyso-Gb3 were considered to be helpful to determine if the novel mutation is a true pathogenic mutation . However, several reports indicated that Gb3, and even lysoGb3 might be normal in certain Fabry patients who had developed significant clinical manifestations with the pathogenic mutations [45, 46]. Renal or cardiac biopsy can provide more information to identify if a novel mutation is a real pathogenic mutation. In the retrospective single-center direct observational study, we reviewed the endomyocardial biopsies of large numbers of later-onset Fabry patients with IVS4 + 919G > A mutation to prove this mutation is a real pathogenic mutation.
Cardiac biopsy of classical Fabry disease patients revealed significant Gb3 accumulation in both endothelium and cardiomyocytes [47–53]. Furthermore, the degree of endothelial Gb3 deposition was even used as a scoring system for monitoring the long-term cardiac therapeutic outcomes of ERT in classic Fabry disease (Thurberg, B.L. et al) . In contrast to classical Fabry disease, cardiac biopsy of the later-onset patients revealed that Gb3 accumulation was confined to the myocardium and did not involve endothelial cells . Other reports have also showed no endothelial Gb3 accumulation in later-onset Fabry disease [56–58]. Therefore, no endothelial Gb3 deposition is expected in later-onset Fabry patients. The cardiac biopsies of our patients showed significant Gb3 accumulation in their cardiomyocytes but not in endothelial cells. It could indicate that IVS4 + 919G > A mutation is a true later-onset Fabry mutation.
Interestingly, a high frequency of hypertension (12 of 22; 54%) and hyperlipidemia (7 of 22; 32%) were noted among these cardiomyopathic patients with the IVS4 + 919G > A mutation. In this study, we did not check other genetic causes of hypertrophic cardiomyopathy. Actually, the exact causal relationship of these factors with hypertrophic cardiomyopathy in our patients has not established. Because most of our patients did not have significant renal impairment, the hypertension was not likely caused by Fabry renopathy. Several studies have indicated that in addition to renal impairment, hypertension could be caused by the imbalance of the autonomic nervous system in patients with Fabry disease . Further studies are required to clarify the relationship between hypertension and the autonomic nervous imbalance in these patients. Furthermore, hypertension might be a predisposing factor to the development of hypertrophic cardiomyopathy for these later-onset Fabry disease patients, especially for the milder Fabry patients. The finding that four out of our five (80%) female patients had significant hypertension supports this finding. In addition, several IVS4 + 919G > A patients in our studies were found to be hypertensive. However, due to the small sample size in our study, we cannot make a definite conclusion regarding the relationship between hypertrophic cardiomyopathy and hypertension, more data will need to be collected and analyzed to clarify this point. Regarding predisposing factors for hypertrophic cardiomyopathy in later-onset Fabry patients, a recent important study, reported by Desnick et al., revealed that as many as 20% of male and 25% of females with later onset Fabry mutations and hypertrophic cardiomyopathy concurrently have a pathogenic or likely pathogenic mutation of the HCM causing gene. Therefore, in addition to Gb3 accumulation, there should be some predisposing factors contributing to the pathogenesis of later-onset Fabry cardiomyopathy.
Regarding hyperlipidemia in Fabry patients, circulating Gb3 has been proved to be primary transported by LDL and HDL lipoproteins (approximately 60% and 30% respectively) . Furthermore, hyperlipidemia was correlated with Fabry disease  and selective LDL-apheresis was shown to be an effective treatment in a Fabry patient with recurrent strokes . However, the causal relationship between hyperlipidemia and hypertrophic cardiomyopathy of later-onset Fabry patients still needs to be clarified.
Interestingly, only scanty Gb3 accumulation could be found in the cardiomyocytes of our three patients who had received the longest period of ERT. This finding is quite different from several previous studies that showed the histological clearance of Gb3 accumulation from cardiomyocytes is usually poor [38, 49, 54, 64]. Does this finding indicate that a longer duration of ERT still has efficacy for Gb3 clearance from cardiomyocytes of later-onset Fabry patients? However, without pre-ERT biopsies, it is impossible to claim ERT was able to clear Gb3 accumulation from the cardiomyocytes of these three patients. More cardiac biopsy data with pre-ERT and post-ERT should be collected to clarify this point.
Recent studies revealed that gadolinium-contrast cardiac MRI is a good method to assess myocardial fibrosis in Fabry disease [34, 65–67]. In patients without fibrosis, ERT resulted in a significant reduction in left ventricular mass and improvement of myocardial function. In contrast, patients with mild or severe fibrosis showed a minor reduction in left ventricular hypertrophy and no improvement in myocardial function. In this study, one patient was found to have significant interstitial fibrosis among his cardiomyocytes by H&E staining of endomyocardial biopsy. However, no significant fibrosis was observed in his heart with late-enhancement technique by gadolinium-contrast cardiac MRI examination. On the other hand, 6 out of the 20 patients received gadolinium-contrast cardiac MRI examination in this study were found to have severe fibrosis (Table 1), but none of them were found to have any significant cardiac fibrosis in their endomyocardial biopsies. This finding indicates that the histological fibrosis of interventricular septum from right ventricular endomyocardial biopsy does not reflect the severity of the fibrosis of the whole heart; most of the fibrosis that significantly affect heart function is usually located in the left ventricular area in Fabry disease.
In this study, we analyzed the pathologic appearance of cardiomyocytes by endomyocardial biopsies in 22 atypical later-onset Fabry disease patients with the Chinese mutation (IVS4 + 919G > A). These data suggest that IVS4 + 919G > A is a real pathogenic mutation with typical Gb3 accumulation and hypertrophic changes in cardiomyocytes. No endothelial Gb3 accumulation was found in cardiac biopsies is consistent with the cardiac pathologic findings of later-onset Fabry disease.
Fabry disease is a rare lysosomal disorder resulting from a genetic deficiency of α-Gal A. The present study used endomyocardial biopsies to confirm that the Chinese Fabry mutation (IVS4 + 919G > A) is a real pathogenic mutation.
The authors thank Ms. Tina, Wu and Mr. Hann-Tyng, Chang for their review and suggestion. The authors acknowledge the support from the industry-hospital cooperative research project between the Taipei Veterans General Hospital and Shire. Our center has received several research grants regarding Fabry disease from Shire Pharmaceuticals and Excelsior Biopharma. Shire had provided English language editing service for this manuscript. However, Shire had no role in the study design; the collection, analysis and interpretation of data; the writing of the manuscript; or the decision to submit the paper for publication. The opinions are those of the authors.
This work was partially supported by the National Science Council, Taiwan (No. NSC-100-2325-B-010-014) and Taipei Veterans General Hospital (No. V101C-129 and V101C-187).
- Meikle PJ, Hopwood JJ, Clague AE, Carey WF: Prevalence of lysosomal storage disorders. JAMA. 1999, 281: 249-254.View ArticlePubMedGoogle Scholar
- Desnick RJ, Wasserstein MP: Fabry disease: clinical features and recent advances in enzyme replacement therapy. Adv Nephrol Necker Hosp. 2001, 31: 317-339.PubMedGoogle Scholar
- Desnick RJ, Brady RO: Fabry disease in childhood. J Pediatr. 2004, 144: S20-S26.View ArticlePubMedGoogle Scholar
- Zarate YA, Hopkin RJ: Fabry's disease. Lancet. 2008, 372: 1427-1435.View ArticlePubMedGoogle Scholar
- Weidemann F, Linhart A, Monserrat L, Strotmann J: Cardiac challenges in patients with Fabry disease. Int J Cardiol. 2010, 141: 3-10.View ArticlePubMedGoogle Scholar
- Bhatia GS, Leahy JF, Connolly DL, Davis RC: Severe left ventricular hypertrophy in Anderson-Fabry disease. Heart. 2004, 90: 1136.View ArticlePubMedPubMed CentralGoogle Scholar
- Linhart A: Treatment of Anderson-Fabry disease. Heart. 2008, 94: 138-139.View ArticlePubMedGoogle Scholar
- Kampmann C, Linhart A, Baehner F, Palecek T, Wiethoff CM, Miebach E, Whybra C, Gal A, Bultas J, Beck M: Onset and progression of the Anderson-Fabry disease related cardiomyopathy. Int J Cardiol. 2008, 130: 367-373.View ArticlePubMedGoogle Scholar
- Imbriaco M, Pisani A, Spinelli L, Cuocolo A, Messalli G, Capuano E, Marmo M, Liuzzi R, Visciano B, Cianciaruso B, Salvatore M: Effects of enzyme-replacement therapy in patients with Anderson-Fabry disease: a prospective long-term cardiac magnetic resonance imaging study. Heart. 2009, 95: 1103-1107.View ArticlePubMedGoogle Scholar
- Monserrat L, Gimeno-Blanes JR, Marin F, Hermida-Prieto M, Garcia-Honrubia A, Perez I, Fernandez X, de Nicolas R, de la Morena G, Paya E, Yague J, Egido J: Prevalence of fabry disease in a cohort of 508 unrelated patients with hypertrophic cardiomyopathy. J Am Coll Cardiol. 2007, 50: 2399-2403.View ArticlePubMedGoogle Scholar
- Nakao S, Takenaka T, Maeda M, Kodama C, Tanaka A, Tahara M, Yoshida A, Kuriyama M, Hayashibe H, Sakuraba H, Tanaka H: An atypical variant of Fabry's disease in men with left ventricular hypertrophy. N Engl J Med. 1995, 333: 288-293.View ArticlePubMedGoogle Scholar
- Sachdev B, Takenaka T, Teraguchi H, Tei C, Lee P, McKenna WJ, Elliott PM: Prevalence of Anderson-Fabry disease in male patients with late onset hypertrophic cardiomyopathy. Circulation. 2002, 105: 1407-1411.View ArticlePubMedGoogle Scholar
- Kotanko P, Kramar R, Devrnja D, Paschke E, Voigtlander T, Auinger M, Pagliardini S, Spada M, Demmelbauer K, Lorenz M, Hauser AC, Kofler HJ, Lhotta K, Neyer U, Pronai W, Wallner M, Wieser C, Wiesholzer M, Zodl H, Fodinger M, Sunder-Plassmann G: Results of a nationwide screening for Anderson-Fabry disease among dialysis patients. J Am Soc Nephrol. 2004, 15: 1323-1329.View ArticlePubMedGoogle Scholar
- Tanaka N, Utsumi K, Seta T, Usuda K, Komaba Y, Katsumata T, Katsura KI, Sakamoto S, Katayama Y: Recurrent strokes in a young adult patient with Fabry's disease. Eur J Neurol. 2005, 12: 486-487.View ArticlePubMedGoogle Scholar
- Nance CS, Klein CJ, Banikazemi M, Dikman SH, Phelps RG, McArthur JC, Rodriguez M, Desnick RJ: Later-onset Fabry disease: an adult variant presenting with the cramp-fasciculation syndrome. Arch Neurol. 2006, 63: 453-457.View ArticlePubMedGoogle Scholar
- Nagueh SF: Fabry disease. Heart. 2003, 89: 819-820.View ArticlePubMedPubMed CentralGoogle Scholar
- Chong KW, Lu YH, Hsu JH, Lo MY, Hsiao CY, Niu DM: High incidence of cardiac variant of fabry disease in Taiwanese revealed by newborn screening. Taiwan Hum Genet Soc Autumn Symp. 2008, 1: 92-98.Google Scholar
- Lin HY, Chong KW, Hsu JH, Yu HC, Shih CC, Huang CH, Lin SJ, Chen CH, Chiang CC, Ho HJ, Lee PC, Kao CH, Cheng KH, Hsueh C, Niu DM: High incidence of the cardiac variant of Fabry disease revealed by newborn screening in the Taiwan Chinese population. Circ Cardiovasc Genet. 2009, 2: 450-456.View ArticlePubMedGoogle Scholar
- Hwu WL, Chien YH, Lee NC, Chiang SC, Dobrovolny R, Huang AC, Yeh HY, Chao MC, Lin SJ, Kitagawa T, Desnick RJ, Hsu LW: Newborn screening for Fabry disease in Taiwan reveals a high incidence of the later-onset GLA mutation c.936 + 919G > A (IVS4 + 919G > A). Hum Mutat. 2009, 30: 1397-1405.View ArticlePubMedPubMed CentralGoogle Scholar
- Chien YH, Lee NC, Chiang SC, Desnick RJ, Hwu WL: Fabry disease: incidence of the common later-onset α-galactosidase A IVS4+919G→A mutation in Taiwanese newborns-superiority of DNA-based to enzyme-based newborn screening for common mutations. Mol Med. 2012, 18: 780-784.View ArticlePubMedPubMed CentralGoogle Scholar
- Lin HY, Liu HC, Huang YH, Liao HC, Hsu TR, Shen CI, Li ST, Li CF, Lee LH, Lee PC, Huang CK, Chiang CC, Lin CY, Lin SP, Niu DM: Effects of enzyme replacement therapy for cardiac-type Fabry patients with a Chinese hotspot late-onset Fabry mutation (IVS4 + 919G > A). BMJ Open. 2013, 3: e003146. doi:10.1136/bmjopen-2013-003146.PubMedPubMed CentralGoogle Scholar
- Lin HY, Huang CH, Yu HC, Chong KW, Hsu JH, Lee PC, Cheng KH, Chiang CC, Ho HJ, Lin SP, Chen SJ, Lin PK, Niu DM: Enzyme assay and clinical assessment in subjects with a Chinese hotspot late-onset Fabry mutation (IVS4 + 919G– > A). J Inherit Metab Dis. 2010, 33: 619-624.View ArticlePubMedGoogle Scholar
- Buja LM: Evaluation of recombinant alpha-galactosidase A therapy for amelioration of the cardiovascular manifestations of Fabry disease: an important role for endomyocardial biopsy. Circulation. 2009, 119: 2539-2541.View ArticlePubMedGoogle Scholar
- Tai CL, Liu MY, Yu HC, Chiang CC, Chiang H, Suen JH, Kao SM, Huang YH, Wu TJ, Yang CF, Tsai FC, Lin CY, Chang JG, Chen HD, Niu DM: The use of high resolution melting analysis to detect Fabry mutations in heterozygous females via dry bloodspots. Clin Chim Acta. 2012, 413: 422-427.View ArticlePubMedGoogle Scholar
- Lee SH, Li CF, Lin HY, Lin CH, Liu HC, Tsai SF, Niu DM: High-throughput detection of common sequence variations of Fabry disease in Taiwan using DNA mass spectrometry. Mol Genet Metab. 2014, 111: 507-512.View ArticlePubMedGoogle Scholar
- Chen CH, Shyu PW, Wu SJ, Sheu SS, Desnick RJ, Hsiao KJ: Identification of a novel point mutation (S65T) in alpha-galactosidase A gene in Chinese patients with Fabry disease: mutations in brief no. 169: online. Hum Mutat. 1998, 11: 328-330.View ArticlePubMedGoogle Scholar
- Rombach SM, Dekker N, Bouwman MG, Linthorst GE, Zwinderman AH, Wijburg FA, Kuiper S, Bergh V, Weerman MA, Groener JE, Poorthuis BJ, Hollak CE, Aerts JM: Plasma globotriaosylsphingosine: diagnostic value and relation to clinical manifestations of Fabry disease. Biochim Biophys Acta. 1802, 2010: 741-748.Google Scholar
- Aerts JM, Groener JE, Kuiper S, Donker-Koopman WE, Strijland A, Ottenhoff R, van Roomen C, Mirzaian M, Wijburg FA, Linthorst GE, Vedder AC, Rombach SM, Cox-Brinkman J, Somerharju P, Boot RG, Hollak CE, Brady RO, Poorthuis BJ: Elevated globotriaosylsphingosine is a hallmark of Fabry disease. Proc Natl Acad Sci U S A. 2008, 105: 2812-2817.View ArticlePubMedPubMed CentralGoogle Scholar
- Liao HC, Huang YH, Chen YJ, Kao SM, Lin HY, Huang CK, Liu HC, Hsu TR, Lin SP, Yang CF, Fann CS, Chiu PC, Hsieh KS, Fu YC, Ke YY, Lin CY, Tsai FJ, Wang CH, Chao MC, Yu WC, Chiang CC, Niu DM: Plasma globotriaosylsphingosine (lysoGb3) could be a biomarker for Fabry disease with a Chinese hotspot late-onset mutation (IVS4 + 919G > A). Clin Chim Acta. 2013, 426: 114-120.View ArticlePubMedGoogle Scholar
- Devereux RB, Alonso DR, Lutas EM, Gottlieb GJ, Campo E, Sachs I, Reichek N: Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am J Cardiol. 1986, 57: 450-458.View ArticlePubMedGoogle Scholar
- Zoccali C, Mallamaci F, Tripepi G, Parlongo S, Cutrupi S, Benedetto FA, Cataliotti A, Malatino LS, Investigators C: Norepinephrine and concentric hypertrophy in patients with end-stage renal disease. Hypertension. 2002, 40: 41-46.View ArticlePubMedGoogle Scholar
- Foppa M, Duncan BB, Rohde LE: Echocardiography-based left ventricular mass estimation. How should we define hypertrophy?. Cardiovasc Ultrasound. 2005, 3: 17.View ArticlePubMedPubMed CentralGoogle Scholar
- Beer M, Weidemann F, Breunig F, Knoll A, Koeppe S, Machann W, Hahn D, Wanner C, Strotmann J, Sandstede J: Impact of enzyme replacement therapy on cardiac morphology and function and late enhancement in Fabry's cardiomyopathy. Am J Cardiol. 2006, 97: 1515-1518.View ArticlePubMedGoogle Scholar
- Weidemann F, Niemann M, Breunig F, Herrmann S, Beer M, Stork S, Voelker W, Ertl G, Wanner C, Strotmann J: Long-term effects of enzyme replacement therapy on fabry cardiomyopathy: evidence for a better outcome with early treatment. Circulation. 2009, 119: 524-529.View ArticlePubMedGoogle Scholar
- Bates MG, Hollingsworth KG, Newman JH, Jakovljevic DG, Blamire AM, Macgowan GA, Keavney BD, Chinnery PF, Turnbull DM, Taylor RW, Trenell MI, Gorman GS: Concentric hypertrophic remodelling and subendocardial dysfunction in mitochondrial DNA point mutation carriers. Eur Heart J Cardiovasc Imaging. 2013, 14: 650-658.View ArticlePubMedPubMed CentralGoogle Scholar
- Cerqueira MD, Weissman NJ, Dilsizian V, Jacobs AK, Kaul S, Laskey WK, Pennell DJ, Rumberger JA, Ryan T, Verani MS: Standardized myocardial segmentation and nomenclature for tomographic imaging of the heart: a statement for healthcare professionals from the Cardiac Imaging Committee of the Council on Clinical Cardiology of the American Heart Association. Circulation. 2002, 105: 539-542.View ArticlePubMedGoogle Scholar
- Tracy RE, Sander GE: Histologically measured cardiomyocyte hypertrophy correlates with body height as strongly as with body mass index. Cardiol Res Pract. 2011, 2011: 658958.PubMedPubMed CentralGoogle Scholar
- Chimenti C, Hamdani N, Boontje NM, DeCobelli F, Esposito A, Bronzwaer JG, Stienen GJ, Russo MA, Paulus WJ, Frustaci A, van der Velden J: Myofilament degradation and dysfunction of human cardiomyocytes in Fabry disease. Am J Pathol. 2008, 172: 1482-1490.View ArticlePubMedPubMed CentralGoogle Scholar
- Chimenti C, Padua L, Pazzaglia C, Morgante E, Centurion C, Antuzzi D, Russo MA, Frustaci A: Cardiac and skeletal myopathy in Fabry disease: a clinicopathologic correlative study. Hum Pathol. 2012, 43: 1444-1452.View ArticlePubMedPubMed CentralGoogle Scholar
- Tracy RE: Cardiomyocyte size estimated from noninvasive measurements of left ventricular wall thickness and chamber diameter. J Am Soc Hypertens. 2012, 6: 185-192.View ArticlePubMedGoogle Scholar
- Tracy RE: Eccentric may differ from concentric left ventricular hypertrophy because of variations in cardiomyocyte numbers. J Card Fail. 2013, 19: 517-522.View ArticlePubMedGoogle Scholar
- Spada M, Pagliardini S, Yasuda M, Tukel T, Thiagarajan G, Sakuraba H, Ponzone A, Desnick RJ: High incidence of later-onset fabry disease revealed by newborn screening. Am J Hum Genet. 2006, 79: 31-40.View ArticlePubMedPubMed CentralGoogle Scholar
- Inoue T, Hattori K, Ihara K, Ishii A, Nakamura K, Hirose S: Newborn screening for Fabry disease in Japan: prevalence and genotypes of Fabry disease in a pilot study. J Hum Genet. 2013, 58: 548-552.View ArticlePubMedGoogle Scholar
- Togawa T, Tsukimura T, Kodama T, Tanaka T, Kawashima I, Saito S, Ohno K, Fukushige T, Kanekura T, Satomura A, Kang DH, Lee BH, Yoo HW, Doi K, Noiri E, Sakuraba H: Fabry disease: biochemical, pathological and structural studies of the alpha-galactosidase A with E66Q amino acid substitution. Mol Genet Metab. 2012, 105: 615-620.View ArticlePubMedGoogle Scholar
- Kitagawa T, Ishige N, Suzuki K, Owada M, Ohashi T, Kobayashi M, Eto Y, Tanaka A, Mills K, Winchester B, Keutzer J: Non-invasive screening method for Fabry disease by measuring globotriaosylceramide in whole urine samples using tandem mass spectrometry. Mol Genet Metab. 2005, 85: 196-202.View ArticlePubMedGoogle Scholar
- Mitobe S, Togawa T, Tsukimura T, Kodama T, Tanaka T, Doi K, Noiri E, Akai Y, Saito Y, Yoshino M, Takenaka T, Saito S, Ohno K, Sakuraba H: Mutant alpha-galactosidase A with M296I does not cause elevation of the plasma globotriaosylsphingosine level. Mol Genet Metab. 2012, 107: 623-626.View ArticlePubMedGoogle Scholar
- Elleder M: Sequelae of storage in Fabry disease–pathology and comparison with other lysosomal storage diseases. Acta Paediatr Suppl. 2003, 92: 46-53. discussion 45.View ArticlePubMedGoogle Scholar
- Faraggiana T, Churg J, Grishman E, Strauss L, Prado A, Bishop DF, Schuchman E, Desnick RJ: Light- and electron-microscopic histochemistry of Fabry's disease. Am J Pathol. 1981, 103: 247-262.PubMedPubMed CentralGoogle Scholar
- Hoffmann B: Fabry disease: recent advances in pathology, diagnosis, treatment and monitoring. Orphanet J Rare Dis. 2009, 4: 21.View ArticlePubMedPubMed CentralGoogle Scholar
- Tuttolomondo A, Pecoraro R, Simonetta I, Miceli S, Pinto A, Licata G: Anderson-Fabry disease: a multiorgan disease. Curr Pharm Des. 2013, 19: 5974-5996.View ArticlePubMedGoogle Scholar
- Germain DP: Fabry disease. Orphanet J Rare Dis. 2010, 5: 30.View ArticlePubMedPubMed CentralGoogle Scholar
- Fischer EG, Moore MJ, Lager DJ: Fabry disease: a morphologic study of 11 cases. Mod Pathol. 2006, 19: 1295-1301.View ArticlePubMedGoogle Scholar
- Eng CM, Guffon N, Wilcox WR, Germain DP, Lee P, Waldek S, Caplan L, Linthorst GE, Desnick RJ: Safety and efficacy of recombinant human alpha-galactosidase A–replacement therapy in Fabry's disease. N Engl J Med. 2001, 345: 9-16.View ArticlePubMedGoogle Scholar
- Thurberg BL, Fallon JT, Mitchell R, Aretz T, Gordon RE, O'Callaghan MW: Cardiac microvascular pathology in Fabry disease: evaluation of endomyocardial biopsies before and after enzyme replacement therapy. Circulation. 2009, 119: 2561-2567.View ArticlePubMedGoogle Scholar
- von Scheidt W, Eng CM, Fitzmaurice TF, Erdmann E, Hubner G, Olsen EG, Christomanou H, Kandolf R, Bishop DF, Desnick RJ: An atypical variant of Fabry's disease with manifestations confined to the myocardium. N Engl J Med. 1991, 324: 395-399.View ArticlePubMedGoogle Scholar
- Frustaci A, Chimenti C, Ricci R, Natale L, Russo MA, Pieroni M, Eng CM, Desnick RJ: Improvement in cardiac function in the cardiac variant of Fabry's disease with galactose-infusion therapy. N Engl J Med. 2001, 345: 25-32.View ArticlePubMedGoogle Scholar
- Takenaka T, Teraguchi H, Yoshida A, Taguchi S, Ninomiya K, Umekita Y, Yoshida H, Horinouchi M, Tabata K, Yonezawa S, Highchi K, Nakao S, Anan R, Minagoe S, Tei C: Terminal stage cardiac findings in patients with cardiac Fabry disease: an electrocardiographic, echocardiographic, and autopsy study. J Cardiol. 2008, 51: 50-59.View ArticlePubMedGoogle Scholar
- Germain DP, Shabbeer J, Cotigny S, Desnick RJ: Fabry disease: twenty novel alpha-galactosidase A mutations and genotype-phenotype correlations in classical and variant phenotypes. Mol Med. 2002, 8: 306-312.PubMedPubMed CentralGoogle Scholar
- Eric A, Aurore S, R F, Vincent P, Jean-Claude B: Autonomic nervous system activity in patients with Fabry disease. Open J Intern Med. 2012, 2: 116-122.View ArticleGoogle Scholar
- Desnick RJ, Doheny D: Targeted sequencing of over 4000 hypertrophic cardiomyopathy (HCM) patients for mutations causing HCM and Fabry disease: HCM mutations frequent n patients with GLA later0onset mutations, polymorphisms, and variant. Mol Genet Adn Metab. 2014, 111: s36-s37.Google Scholar
- Desnick RJ, Ioannou YA, Eng CM: α-Galactosidase a deficiency: Fabry disease (2001). Metab Mol Bases Inherited Dis. 2001, 8th edn: 3373-3774.Google Scholar
- Cartwright DJ, Cole AL, Cousins AJ, Lee PJ: Raised HDL cholesterol in Fabry disease: response to enzyme replacement therapy. J Inherit Metab Dis. 2004, 27: 791-793.View ArticlePubMedGoogle Scholar
- Utsumi K, Seta T, Katsumata T, Komaba Y, Igarashi H, Katsura KI, Iino Y, Katayama Y: Effect of selective LDL-apheresis in a Fabry patient with recurrent strokes. Eur J Neurol. 2006, 13: 429-430.View ArticlePubMedGoogle Scholar
- Tondel C, Bostad L, Larsen KK, Hirth A, Vikse BE, Houge G, Svarstad E: Agalsidase benefits renal histology in young patients with Fabry disease. J Am Soc Nephrol. 2013, 24: 137-148.View ArticlePubMedGoogle Scholar
- Weidemann F, Breunig F, Beer M, Sandstede J, Stork S, Voelker W, Ertl G, Knoll A, Wanner C, Strotmann JM: The variation of morphological and functional cardiac manifestation in Fabry disease: potential implications for the time course of the disease. Eur Heart J. 2005, 26: 1221-1227.View ArticlePubMedGoogle Scholar
- Sado DM, White SK, Piechnik SK, Banypersad SM, Treibel T, Captur G, Fontana M, Maestrini V, Flett AS, Robson MD, Lachmann RH, Murphy E, Mehta A, Hughes D, Neubauer S, Elliott PM, Moon JC: Identification and assessment of Anderson-Fabry disease by cardiovascular magnetic resonance noncontrast myocardial T1 mapping. Circ Cardiovasc Imaging. 2013, 6: 392-398.View ArticlePubMedGoogle Scholar
- Koeppe S, Neubauer H, Breunig F, Weidemann F, Wanner C, Sandstede J, Machann W, Hahn D, Kostler H, Beer M: MR-based analysis of regional cardiac function in relation to cellular integrity in Fabry disease. Int J Cardiol. 2012, 160: 53-58.View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.